SF4025 Summary

• Prohibits municipalities from asserting or enforcing released claims against settling defendants (Johnson & Johnson, AmerisourceBergen, Cardinal Health, and McKesson) in opioid litigation.

• Establishes two accounts within the opiate epidemic response fund: a registration and license fee account and a settlement account to separately track opioid settlement proceeds.

• Transfers money from a separate settlement account in the state treasury to the opiate epidemic response fund's settlement account and eliminates the separate account.

• Delays the reduction of pharmacy license fees and repeal of the opioid manufacturer registration fee from July 1, 2024 to July 1, 2031, or until the state receives $250,000,000 total from settlements and fees.

• Requires municipalities receiving direct opioid settlement payments to report annually to the commissioner of human services on expenditures, services funded, and measurable outcomes related to opioid remediation.